Key Highlights
- Trading commenced at $277.32, representing a significant decline from the 52-week peak of $606.36
- Analysts reduced price targets — JPMorgan to $389, Truist to $370, UBS to $410
- Weiss Ratings issued a downgrade to Sell rating in early March
- Q4 earnings per share of $2.11 marginally exceeded projections; revenue climbed 12.3% to $113.73 billion
- MarketBeat consensus shows Moderate Buy with a $372.13 average price target
UnitedHealth Group (UNH) continues to face significant headwinds. Shares began Monday’s session at $277.32, trading below the 50-day moving average of $297.19 and the 200-day moving average of $324.39.
The current price represents a substantial retreat from the 52-week high of $606.36, while the 52-week low stands at $234.60.
Market capitalization currently totals $251.71 billion. The company carries a price-to-earnings ratio of 21.02 alongside a beta of 0.41.
The debt-to-equity ratio registers at 0.72, while both current and quick ratios measure 0.79.
January brought Q4 earnings results showing $2.11 per share, narrowly surpassing the consensus estimate of $2.09. Revenue reached $113.73 billion, representing a 12.3% year-over-year increase and exceeding analyst projections.
However, the Q4 EPS figure marks a substantial decline from $6.81 reported during the corresponding quarter of the previous year.
Wall Street Lowers Price Expectations
Major financial institutions have reduced their outlook for the stock in recent months.
JPMorgan lowered its target from $425 to $389, Morgan Stanley adjusted downward from $411 to $409, and UBS reduced expectations from $430 to $410. Truist implemented the most aggressive reduction, moving from $410 to $370. Each of these firms retained Buy or Overweight ratings.
Weiss Ratings took a more bearish stance, moving UNH from Hold to Sell during early March.
MarketBeat’s current consensus reflects a Moderate Buy rating, composed of 17 Buy ratings, 8 Holds, and 2 Sells. The average 12-month price target stands at $372.13 — suggesting approximately 34% potential upside from present levels.
Institutional investors have shown mixed activity. Wealth Enhancement Advisory Services reduced its position by 40.6% during Q4, liquidating 170,643 shares. Conversely, Norges Bank, Berkshire Hathaway, and Capital Research Global Investors either expanded or established positions throughout 2024. Institutional ownership totals 87.86% of outstanding shares.
Ongoing Regulatory Challenges
DOJ investigation into Medicare Advantage reimbursement practices remains a factor affecting investor sentiment. While the company has secured at least one favorable legal outcome in the case, broader regulatory examination of prior-authorization protocols and coverage denial procedures persists.
Executives have disclosed intentions to reduce certain Medicare Advantage membership and adjust product pricing in response to changing cost dynamics.
Management provided FY2026 EPS guidance of approximately $17.75. Wall Street analysts project full-year EPS of $29.54 for the current fiscal year on average.
UNH distributed a quarterly dividend of $2.21 per share on March 17, yielding approximately 3.2% on an annualized basis. The current payout ratio measures 67.02%.
Among favorable developments, UnitedHealth recently unveiled a nationwide expansion of its doula benefit program, an initiative that may enhance member retention and deliver improved outcomes within its value-based care framework.
